The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.
Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.